DBV Technologies | DBVT - Equity Capital And Reserves


DBV Technologies reported $160.4M in Equity Capital and Reserves for its fiscal quarter ending in June of 2026.





Equity Capital And Reserves Change Date
Acadia Pharmaceuticals USD 1.31B 58.54M Jun/2026
Alnylam Pharmaceuticals USD 1.35B 278.74M Jun/2026
Amarin USD 443.62M 5.8M Jun/2026
BioCryst Pharmaceuticals USD -454.29M 99.55M Jun/2026
BioMarin Pharmaceutical USD 6.21B 125.11M Mar/2026
DBV Technologies USD 160.4M 47.5M Jun/2026
Galectin Therapeutics USD -83.87M 11.06M Jun/2024
Halozyme Therapeutics USD 219.64M 170.82M Mar/2026
Incyte USD 6.34B 721.58M Jun/2026
Insmed USD 757.49M 52.64M Jun/2026
Ionis Pharmaceuticals USD 439.74M 51.68M Jun/2026
Neurocrine Biosciences USD 3.69B 286.2M Jun/2026
PTC Therapeutics USD -165.36M 15.1M Jun/2026
Sarepta Therapeutics USD 1.53B 22.7M Jun/2026
Ultragenyx Pharmaceutical USD -291M 55M Jun/2026
United Therapeutics USD 6.4B 499.2M Jun/2026